{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T01:49:46Z","timestamp":1772848186379,"version":"3.50.1"},"reference-count":26,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,30]],"date-time":"2022-01-30T00:00:00Z","timestamp":1643500800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Saudi Journal of Biological Sciences"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.sjbs.2022.01.058","type":"journal-article","created":{"date-parts":[[2022,2,4]],"date-time":"2022-02-04T02:38:47Z","timestamp":1643942327000},"page":"3313-3325","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Development of antidiabetic drugs from benzamide derivatives as glucokinase activator: A computational approach"],"prefix":"10.1016","volume":"29","author":[{"given":"Amena","family":"Ali","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.sjbs.2022.01.058_b0005","doi-asserted-by":"crossref","first-page":"129861","DOI":"10.1016\/j.molstruc.2020.129861","article-title":"Integrated computational approaches on pyrazoline derivatives as B-Raf kinase inhibitors for the development of novel anticancer agents","volume":"1230","author":"Ali","year":"2021","journal-title":"J. Mol. Struct."},{"key":"10.1016\/j.sjbs.2022.01.058_b0010","doi-asserted-by":"crossref","unstructured":"American Diabetes Association, 2009. Diagnosis and classification of diabetes mellitus. Diabetes Care. 32, S62-S67.","DOI":"10.2337\/dc09-S062"},{"issue":"19","key":"10.1016\/j.sjbs.2022.01.058_b0015","doi-asserted-by":"crossref","first-page":"7916","DOI":"10.1021\/jm5009902","article-title":"Identification of the first inhibitor of the GBP1:PIM1 interaction. Implications for the development of a new class of anticancer agents against paclitaxel resistant cancer cells","volume":"57","author":"Andreoli","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.sjbs.2022.01.058_b0020","doi-asserted-by":"crossref","first-page":"5466","DOI":"10.1021\/bi900374c","article-title":"Binding kinetics of glucose and allosteric activators to human glucokinase reveal multiple conformational states","volume":"48","author":"Antoine","year":"2009","journal-title":"Biochemistry"},{"key":"10.1016\/j.sjbs.2022.01.058_b0025","doi-asserted-by":"crossref","first-page":"6142","DOI":"10.1021\/jm900839k","article-title":"Investigation of functionally liver selective glucokinase activators for the treatment of type 2 diabetes","volume":"52","author":"Bebernitz","year":"2009","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.sjbs.2022.01.058_b0030","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.compbiolchem.2018.02.018","article-title":"Design, synthesis and biological evaluation of novel thiazol-2-yl benzamide derivatives as glucokinase activators","volume":"73","author":"Charaya","year":"2018","journal-title":"Comput. Biol. Chem."},{"key":"10.1016\/j.sjbs.2022.01.058_b0035","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1007\/s11224-019-01414-w","article-title":"Diarylthiazole and diarylimidazole selective COX-1 inhibitor analysis through pharmacophore modeling, virtual screening, and DFT-based approaches","volume":"30","author":"Crisan","year":"2019","journal-title":"Struc. Chem."},{"key":"10.1016\/j.sjbs.2022.01.058_b0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13065-019-0532-8","article-title":"Design, synthesis and evaluation of novel 3,5-disubstituted benzamide derivatives as allosteric glucokinase activators","volume":"13","author":"Grewal","year":"2019","journal-title":"BMC Chem."},{"key":"10.1016\/j.sjbs.2022.01.058_b0045","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1080\/10629360903568697","article-title":"QSAR with quantum topological molecular similarity indices: toxicity of aromatic aldehydes to Tetrahymena pyriformis","volume":"21","author":"Kar","year":"2010","journal-title":"SAR QSAR Environ. Res."},{"key":"10.1016\/j.sjbs.2022.01.058_b0050","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1016\/j.bmc.2012.03.008","article-title":"Design, synthesis, and pharmacological evaluation of benzamide derivatives as glucokinase activators","volume":"20","author":"Mao","year":"2012","journal-title":"Bioorg. Med. Chem"},{"key":"10.1016\/j.sjbs.2022.01.058_b0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/iub.411","article-title":"Liver glucokinase: An overview on the regulatory mechanisms of its activity","volume":"63","author":"Massa","year":"2011","journal-title":"IUBMB Life."},{"key":"10.1016\/j.sjbs.2022.01.058_b0060","first-page":"43","article-title":"Glucokinase activators (GKAs) promise a new pharmacotherapy for diabetics. F1000 Med","volume":"2","author":"Matschinsky","year":"2010","journal-title":"Rep"},{"key":"10.1016\/j.sjbs.2022.01.058_b0065","doi-asserted-by":"crossref","first-page":"223","DOI":"10.2337\/diab.45.2.223","article-title":"A lesson in metabolic regulation inspired by the glucokinase glucose sensor paradigm","volume":"45","author":"Matschinsky","year":"1996","journal-title":"Diabetes"},{"key":"10.1016\/j.sjbs.2022.01.058_b0070","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1007\/s12272-012-1201-9","article-title":"Identification of YH-GKA, a novel benzamide glucokinase activator as therapeutic candidate for type 2 diabetes mellitus","volume":"35","author":"Park","year":"2012","journal-title":"Arch. Pharm. Res."},{"key":"10.1016\/j.sjbs.2022.01.058_b0075","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1021\/ml5004712","article-title":"Design and synthesis of acetylenyl benzamide derivatives as novel glucokinase activators for the treatment of T2DM","volume":"6","author":"Park","year":"2015","journal-title":"ACS Med. Chem. Lett."},{"issue":"7","key":"10.1016\/j.sjbs.2022.01.058_b0080","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1016\/j.bmc.2014.02.009","article-title":"Discovery of 3-(4-methanesulfonylphenoxy)-N-[1-(2-methoxy-ethoxymethyl)-1H-pyrazol-3-yl]-5-(3-methylpyridin-2-yl)-benzamide as a novel glucokinase activator (GKA) for the treatment of type 2 diabetes mellitus","volume":"22","author":"Park","year":"2014","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.sjbs.2022.01.058_b0085","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.bmcl.2012.11.018","article-title":"Discovery of a novel phenylethyl benzamide glucokinase activator for the treatment of type 2 diabetes mellitus","volume":"23","author":"Park","year":"2013","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.sjbs.2022.01.058_b0090","doi-asserted-by":"crossref","first-page":"56344","DOI":"10.1039\/C7RA10870B","article-title":"Molecular modeling studies of quinazolinone derivatives as novel PI3Kd selective inhibitors","volume":"7","author":"Peng","year":"2017","journal-title":"RSC Adv."},{"issue":"9","key":"10.1016\/j.sjbs.2022.01.058_b0095","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1039\/c1md00116g","article-title":"Designing glucokinase activators with reduced hypoglycemia risk: discovery of N, N-dimethyl-5-(2-methyl-6-((5-methylpyrazin-2-yl)-carbamoyl)benzofuran-4-yloxy)pyrimidine-2-carboxamide as a clinical candidate for the treatment of type 2 diabetes mellitus","volume":"2","author":"Pfefferkorn","year":"2011","journal-title":"Med. Chem. Commun."},{"key":"10.1016\/j.sjbs.2022.01.058_b0100","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1021\/jm2014887","article-title":"Discovery of (S)-6-(3cyclopentyl-2-(4-(trifluoromethyl)-1H-imidazol-1-yl)propanamido)nicotinic acid as a hepatoselective glucokinase activator clinical candidate for treating type 2 diabetes mellitus","volume":"55","author":"Pfefferkorn","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.sjbs.2022.01.058_b0105","first-page":"157","article-title":"Pharmacophore and Virtual Screening of JAK3 inhibitors","volume":"10","author":"Rajeswari","year":"2014","journal-title":"Bioinfo."},{"key":"10.1016\/j.sjbs.2022.01.058_b0110","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0101405","article-title":"Dynamic and multi-pharmacophore modeling for designing polo-box domain inhibitors","volume":"9","author":"Sakkiah","year":"2014","journal-title":"PloS One"},{"key":"10.1016\/j.sjbs.2022.01.058_b0115","unstructured":"Schrodinger. 2017. LigPrep, Schrodinger, LLC, NY."},{"key":"10.1016\/j.sjbs.2022.01.058_b0120","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1038\/nature09573","article-title":"Crystal structure of bacterial RNA polymerase bound with a transcription inhibitor protein","volume":"468","author":"Tagami","year":"2010","journal-title":"Nature"},{"issue":"2011","key":"10.1016\/j.sjbs.2022.01.058_b0125","first-page":"20120488","article-title":"Density functional theory across chemistry, physics and biology","volume":"372","author":"Van Mourik","year":"2014","journal-title":"Philosophical Trans. Ser. A, Math. Phys. Eng. Sci."},{"key":"10.1016\/j.sjbs.2022.01.058_b0130","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1039\/c1md00090j","article-title":"Overcoming retinoic acid receptor-\u03b1 based testicular toxicity in the optimisation of glucokinase activators","volume":"2","author":"Waring","year":"2011","journal-title":"Med. Chem. Commun."}],"container-title":["Saudi Journal of Biological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1319562X22000687?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1319562X22000687?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T17:27:10Z","timestamp":1761154030000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1319562X22000687"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["S1319562X22000687"],"URL":"https:\/\/doi.org\/10.1016\/j.sjbs.2022.01.058","relation":{},"ISSN":["1319-562X"],"issn-type":[{"value":"1319-562X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of antidiabetic drugs from benzamide derivatives as glucokinase activator: A computational approach","name":"articletitle","label":"Article Title"},{"value":"Saudi Journal of Biological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.sjbs.2022.01.058","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author. Published by Elsevier B.V. on behalf of King Saud University.","name":"copyright","label":"Copyright"}]}}